Yuki Kageyama to Survival Analysis
This is a "connection" page, showing publications Yuki Kageyama has written about Survival Analysis.
Connection Strength
0.157
-
Favorable outcome of preoperative low dose chemoradiotherapy against muscle-invasive bladder cancer. Am J Clin Oncol. 2003 Oct; 26(5):504-7.
Score: 0.042
-
Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. J Immunother Cancer. 2021 02; 9(2).
Score: 0.035
-
Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J Urol. 2008 Aug; 180(2):618-21; discussion 621.
Score: 0.015
-
Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis. Urology. 2008 Aug; 72(2):384-8.
Score: 0.014
-
C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008 Apr; 101(8):978-81.
Score: 0.014
-
HSP60 may predict good pathological response to neoadjuvant chemoradiotherapy in bladder cancer. Jpn J Clin Oncol. 2007 Jan; 37(1):56-61.
Score: 0.013
-
Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU Int. 2006 Jun; 97(6):1322-6.
Score: 0.013
-
Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003 Nov 15; 9(15):5501-7.
Score: 0.011